- Home
- YMAB vs FF Comparison
YMAB vs FF Comparison
Compare YMAB & FF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- FF
- Stock Information
- Founded
- YMAB 2015
- FF N/A
- Country
- YMAB United States
- FF United States
- Employees
- YMAB N/A
- FF N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- FF Major Chemicals
- Sector
- YMAB Health Care
- FF Industrials
- Exchange
- YMAB Nasdaq
- FF Nasdaq
- Market Cap
- YMAB 270.5M
- FF N/A
- IPO Year
- YMAB 2018
- FF N/A
- Fundamental
- Price
- YMAB $4.43
- FF $3.92
- Analyst Decision
- YMAB Buy
- FF Strong Buy
- Analyst Count
- YMAB 11
- FF 1
- Target Price
- YMAB $18.73
- FF $0.80
- AVG Volume (30 Days)
- YMAB 328.7K
- FF 332.0K
- Earning Date
- YMAB 03-04-2025
- FF 03-28-2025
- Dividend Yield
- YMAB N/A
- FF 6.13%
- EPS Growth
- YMAB N/A
- FF N/A
- EPS
- YMAB N/A
- FF 0.35
- Revenue
- YMAB $87,685,000.00
- FF $243,339,000.00
- Revenue This Year
- YMAB $20.07
- FF N/A
- Revenue Next Year
- YMAB $8.76
- FF N/A
- P/E Ratio
- YMAB N/A
- FF $11.89
- Revenue Growth
- YMAB 3.38
- FF N/A
- 52 Week Low
- YMAB $4.25
- FF $3.89
- 52 Week High
- YMAB $17.78
- FF $8.36
- Technical
- Relative Strength Index (RSI)
- YMAB 34.59
- FF 31.91
- Support Level
- YMAB $4.65
- FF $4.08
- Resistance Level
- YMAB $5.25
- FF $4.44
- Average True Range (ATR)
- YMAB 0.30
- FF 0.18
- MACD
- YMAB 0.03
- FF 0.01
- Stochastic Oscillator
- YMAB 6.32
- FF 3.45
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.